KPV
Lys-Pro-Val / KPV Tripeptide
KPV is a naturally occurring anti-inflammatory tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically representing residues 11-13 of the full hormone sequence. Despite lacking the melanocortin receptor binding core of alpha-MSH, KPV retains potent anti-inflammatory activity through direct NF-kB inhibition and has shown particular promise in inflammatory bowel disease and mucosal inflammation research. It represents a rare example of a minimal bioactive peptide fragment that maintains therapeutic activity without the parent molecule's hormonal effects.
Mechanism of Action
C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte stimulating hormone). Potent anti-inflammatory that inhibits NF-kB translocation to the nucleus, reducing TNF-alpha, IL-6, and IL-1 beta production. Crosses the blood-brain barrier.
Research Protocols
For research purposes only. Not medical advice.
Research protocols use 200-500mcg daily via subcutaneous injection or oral capsule. For gut inflammation, oral or rectal administration studied at 100-400mcg. Cycles of 4-8 weeks.
Research Notes
Clinical Research Status
KPV has not entered formal clinical trials as a standalone therapeutic but is under active preclinical investigation for inflammatory bowel disease, colitis, and dermatological conditions. Research groups at Tulane University and the University of Colorado have published extensively on its anti-inflammatory mechanisms in colonic tissue. The peptide is being explored in nanoparticle delivery systems for targeted oral delivery to inflamed intestinal mucosa. Its status remains investigational with no regulatory approvals in any jurisdiction.
Key Published Findings
A 2003 study in the Journal of Biological Chemistry demonstrated KPV enters cells and translocates to the nucleus where it directly inhibits NF-kB activation and subsequent pro-inflammatory cytokine transcription (IL-1beta, IL-6, TNF-alpha). Research published in Inflammatory Bowel Diseases showed KPV significantly reduced colonic inflammation in DSS-induced colitis models, with efficacy via both systemic injection and oral administration. Antimicrobial studies demonstrated activity against Staphylococcus aureus and Candida albicans through mechanisms independent of its anti-inflammatory pathway. A 2020 nanoparticle study showed orally-delivered KPV in hyaluronic acid-functionalized nanoparticles specifically accumulated in inflamed colonic tissue.
Safety Profile
KPV has demonstrated an excellent safety profile in all available preclinical studies with no observed toxicity at doses far exceeding therapeutic concentrations. Unlike full-length alpha-MSH, KPV has minimal melanotropic activity and does not cause skin pigmentation changes, sexual arousal, or other melanocortin-mediated effects. The tripeptide is rapidly metabolized by standard aminopeptidases, reducing risk of systemic accumulation. No adverse effects have been reported in community use, though formal human safety studies with defined endpoints have not been published.
Drug Interactions & Contraindications
No formal drug interaction studies exist, though KPV's NF-kB inhibition could theoretically potentiate other anti-inflammatory or immunosuppressive agents (TNF-alpha inhibitors, corticosteroids). Patients on biologic immunosuppressants for IBD (infliximab, adalimumab) should exercise caution with concurrent KPV due to potentially additive immunosuppression. Its antimicrobial properties suggest it should not interfere with antibiotic therapy and may provide synergistic benefit. No absolute contraindications have been identified in published literature.
Comparison to Related Compounds
Unlike its parent molecule alpha-MSH, KPV does not bind melanocortin receptors and produces no tanning, appetite suppression, or sexual side effects, isolating only the anti-inflammatory activity. Compared to BPC-157 (another gut-protective peptide), KPV works through a distinct mechanism (NF-kB inhibition vs. nitric oxide pathway modulation) and is more specifically anti-inflammatory rather than broadly tissue-protective. Relative to mesalamine (5-ASA) used in IBD, KPV acts upstream at the NF-kB level rather than downstream at the prostaglandin level. Its minimal size (3 amino acids) makes it exceptionally stable and inexpensive to synthesize compared to larger therapeutic peptides.
Community Observations
Users most commonly employ KPV for gut inflammation, often administered orally in capsule form (200-500 mcg) or subcutaneously (200-400 mcg) for systemic anti-inflammatory effects. Reports suggest noticeable improvement in IBS and IBD symptoms within 1-2 weeks of consistent use, particularly regarding abdominal pain and stool consistency. It is frequently combined with BPC-157 in gut-healing protocols, with users reporting synergistic benefits from the complementary mechanisms. Some practitioners recommend it for post-infectious gut inflammation and as part of mold/biotoxin illness recovery protocols.
Half-Life
~30 minutes
Reconstitution
Bacteriostatic water (BAC)
Storage
Lyophilized
Refrigerate 2-8C up to 12 months.
Reconstituted
Refrigerate 2-8C. Use within 14 days.
US Legal Status
Also Known As
PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.
Read full disclaimer